Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
See Latest ArticlesMonitoring Of Severe Crohn's Colitis Treated With Intravenous Corticosteroids By C-Reactive Protein: Results Of A Prospective Study
The Internet Journal of Gastroenterology, 06/30/09
Karoui S et al. - Monitoring a severe Crohn's colitis patients with CRP measurement is helpful to predict the unfavourable outcome and to select the patients in whom a more aggressive medical treatment should be considered at an early stage.
Related Articles
A Case-Control Study on Risk Factors of Osteoporosis in Patients with Crohn's Disease
Archives of Iranian Medicine, 11/13/09
Relevance Score: 67%
Medical Management of Ulcerative Colitis
Digestive Diseases, 11/09/09
Relevance Score: 67%
Oxidized Form Of A Common Vitamin May Bring Relief For Ulcerative Colitis
ScienceDaily, 10/02/09
Relevance Score: 67%
Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis
The European Journal of Health Economics, 10/29/09
Relevance Score: 66%
Ulcerative Colitis Treatment Reduces Need For Surgery By Almost Half, Study Suggests
ScienceDaily, 10/02/09
Relevance Score: 66%
Today in Inflammatory Bowel Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Insights into IBD pathogenesis
Current Gastroenterology Reports, 12/09/09
Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and crohns disease)
Current Gastroenterology Reports, 12/09/09
Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease
Clinical and Experimental Gastroenterology, 12/09/09
Today in Pharmacology/kinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease
Clinical and Experimental Gastroenterology, 12/09/09
Delayed-Release Oral Mesalamine 4.8 g/day (800-mg Tablet) Is Effective for Patients With Moderately Active Ulcerative Colitis
Gastroenterology, 12/09/09
Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial
Gastroenterology, 12/09/09
Sponsor
Article Search
Sponsor